Who Developed Tesamorelin?
Short answer: Theratechnologies, a Montreal company, developed tesamorelin under the code TH9507 as a stabilised analogue of the 44-residue human growth-hormone-releasing hormone. It took the compound through the phase 3 trials published by Falutz and colleagues and to FDA approval as Egrifta in 2010.
The code TH9507 appears in the early pharmacology papers and trial registrations, so a reader searching the literature needs both names. The marketed brand later changed formulation and name variants, but the molecule is the same.
The compound is a modified natural hormone rather than a new sequence: the modification, described on its own page, protects the first residues from enzymatic cleavage.
REVIVE LAB UAE supplies the pack for laboratory research use only. It is not for human or veterinary use, and no dosing, administration or protocol guidance is provided.
Tesamorelin Pack 20 mg — REVIVE LAB UAE
AED 1010 · Lot-specific COA on request · Cash on delivery or USDT (5% off) Order Tesamorelin Pack UAE — Live Stock & Pricing
AED 1010 · Lot-specific COA on request · Cash on delivery or USDT (5% off) Order Tesamorelin Pack UAE — Live Stock & Pricing
Research-Use Only Disclaimer: This page is published for laboratory and scientific research information purposes only. Nothing here constitutes medical advice, dosing guidance, or a therapeutic recommendation. Products supplied by REVIVE LAB UAE (revivelab.ae) — where applicable — are sold strictly as reference materials for research use, not for human or veterinary consumption. Buyers and readers are solely responsible for compliance with applicable UAE laws and institutional research ethics requirements.